Context Therapeutics Inc.CNTXNASDAQ
Loading
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Gross Profit Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +404.08% | +265.88% | +496.19% | +73.20% | +18.27% |
| Weighted Average Shares Diluted Growth | +404.08% | +265.88% | +496.19% | +73.20% | +18.27% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | +275.53% | +510.90% | +741.19% | -15.15% | -8.22% |
| Book Value per Share Growth | -9.51% | +119.34% | +80.75% | -52.86% | -26.22% |
| Debt Growth | +0.00% | +0.00% | +0.00% | +0.00% | -42.63% |
| R&D Expense Growth | +275.13% | -52.50% | +75.50% | +465.56% | -48.16% |
| SG&A Expenses Growth | +10.67% | +9.85% | +11.67% | +13.14% | +0.65% |